ArticleThe Laryngoscope2026
Office-Based Blue Laser Therapy and Steroid Injection of Hemorrhagic and Nonhemorrhagic Vocal Fold Polyp.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation between the morphology of vocal fold polyps, hemorrhagic versus nonhemorrhagic, and treatment outcome following office-based blue laser therapy with intralesional steroid injection.
methodsAll the medical records and video recordings of patients diagnosed with vocal fold polyps who underwent office-based blue laser therapy with intralesional steroid injection at a tertiary referral center between June 2023 and August 2025 were reviewed. Vocal fold polyps were classified as hemorrhagic versus nonhemorrhagic. The treatment outcome measures included the Voice Handicap Index-10 (VHI-10) score, acoustic parameters, maximum phonation time (MPT), and disease regression. The mean follow-up period was 12.79 ± 12.31 weeks.
resultsA total of 29 patients with vocal fold polyps were included in the study. Twenty-one patients had hemorrhagic polyps, while the remaining had nonhemorrhagic polyps. No significant differences in the demographic variables were noted between the two subgroups. The mean VHI-10 score in the hemorrhagic polyp subgroup decreased by 10.2 ± 6.76 points, compared to 6.33 ± 7.14 points in the nonhemorrhagic subgroup (p = 0.208). There was a significant difference in complete disease regression between the hemorrhagic and nonhemorrhagic subgroups (95.2% vs. 62.5% p = 0.022). No significant differences were observed in any of the acoustic parameters between the two subgroups except for jitter (p = 0.017).
conclusionThe results of this investigation indicate that hemorrhagic vocal fold polyps respond better to office-based blue laser therapy with intralesional steroid injection than nonhemorrhagic polyps. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.